These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 28810803)

  • 21. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive T-Cell Therapy for Solid Tumors.
    Yeku O; Li X; Brentjens RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
    Geyer MB; Brentjens RJ
    Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKG2D CARs as cell therapy for cancer.
    Sentman CL; Meehan KR
    Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New development in CAR-T cell therapy.
    Wang Z; Wu Z; Liu Y; Han W
    J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors.
    Han S; Latchoumanin O; Wu G; Zhou G; Hebbard L; George J; Qiao L
    Cancer Lett; 2017 Apr; 390():188-200. PubMed ID: 28089834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Strategies for the Treatment of Solid Tumors with CAR-T Cells.
    Zhang H; Ye ZL; Yuan ZG; Luo ZQ; Jin HJ; Qian QJ
    Int J Biol Sci; 2016; 12(6):718-29. PubMed ID: 27194949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
    Wang J; Zhou P
    Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
    Catros V
    Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.